Drugs / Leptin
Leptin
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04374500 | Jan → Oct 2006 | obesity disorder | Stefan Soderberg | Completed | No outcome recorded |
| Phase 12 trials · 1 missed | ||||||
| Phase 1 | NCT01268644 | Sep 2010 → Jan 2013 | type 1 diabetes mellitus | University of Texas Southwestern Medical Center | Terminated | Missed primary |
| Phase 1 | NCT01275053 | Jul 2002 → Dec 2013 | obesity disorder | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00710814 | Apr 2008 → Aug 2012 | obesity disorder | Columbia University | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01155180 | Jul 2008 → Dec 2012 | obesity disorder | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00362440 | Aug 2006 → May 2011 | lipodystrophy | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00027456 | Nov 2001 → Dec 2002 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00050791 | Mar 2001 → Nov 2006 | obesity disorder | Rockefeller University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00073242 | Jul 2000 → Jul 2015 | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00121433 | Sep → Dec 2004 | — | University of Michigan | Completed | No outcome recorded |
| Phase not applicable2 trials · 1 missed | ||||||
| — | NCT00265980 | Jul 2002 → Jul 2013 | obesity disorder | Columbia University | Terminated | No outcome recorded Stop: Business |
| — | NCT01207934 | Aug 1998 → Jul 2000 | type 2 diabetes mellitus | Washington University School of Medicine | Completed | Missed primary |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT00461552 Comparator | Jan 2003 → Sep 2014 | HIV infectious disease, lipodystrophy | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00896298 Comparator | Apr 2006 → Nov 2014 | generalized lipodystrophy, partial lipodystrophy | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT01257841 Comparator | Nov 2002 → Dec 2003 | — | Massachusetts General Hospital | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leptin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00710814 ↗ |
| Known as | (r-met hu) leptin | “30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days” NCT01207934 ↗ |
| Known as | A100 | “A synthetic form of leptin (A-100), an investigational drug and has not yet been approved by the Food and Drug Administration (FDA), will be administered to participants in this study.” NCT01275053 ↗1“Therefore, a strategy to achieve physiological concentrations of leptin hormone using recombinant leptin (A100, recombinant methionyl-human leptin) will be justified.” NCT00027456 ↗ |
| Known as | metreleptin | “To address these questions, we performed a randomized, double-blinded, placebo-controlled trial of recombinant methionyl-human leptin (metreleptin) administration in...” PMID 23382191 ↗ Feb 2013 |
| Known as | recombinant methionyl human leptin | “The researchers plan to enroll a total of 15 non-obese (BMI \< 27 kg/m2) otherwise healthy adults into a randomized, double-blinded, cross-over study of the impact of...” NCT00121433 ↗1“Therefore, a strategy to achieve physiological concentrations of leptin hormone using recombinant leptin (A100, recombinant methionyl-human leptin) will be justified.” NCT00027456 ↗ |
| Action | Activate | “by activating some of the down-stream molecules in insulin signaling cascade” NCT00027456 ↗ |
| Modality | Protein / enzyme biologic | “using recombinant leptin” NCT00027456 ↗ |
| Route | Subcutaneous | “The medication will be administered subcutaneously in two divided doses.” NCT00027456 ↗ |